帕利哌酮缓释片治疗首发精神分裂症的疗效比较  

Paley risperidone sustained-release tablets in treatment of patients with first-onset schizophrenia compared

作　　者：王东平[1] 卫世强[2] 詹合琴[3] 

机构地区：[1]新乡医学院第二附属医院早期干预二科,453002 [2]解放军三七一中心医院心血管内科 [3]新乡医学院药学院药理学教研室

出　　处：《中国现代药物应用》2013年第10期20-21,共2页Chinese Journal of Modern Drug Application

摘　　要：目的比较帕利哌酮缓释片与奋乃静治疗首发精神分裂症的疗效及安全性。方法将69例首发精神分裂症住院患者,随机分为帕利哌酮缓释片组34例和奋乃静组35例,分别采用帕利哌酮缓释片和奋乃静治疗,采用阳性与阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)于治疗前后评定临床疗效和不良反应。治疗时间为8周。结果两组治疗后的PANSS评分均较治疗前显著降低(P<0.01)。帕利哌酮缓释片组和奋乃静组的显效率分别为77.0%和71.7%,总有效率分别为94.8%和91.9%,两组比较差异无统计学意义(P>0.05)。两组TESS均分也差异无统计学意义(P>0.05)。结论帕利哌酮缓释片治疗首发精神分裂症效果肯定,安全性高,为临床治疗精神分裂症提供一种新选择。Objective To compare the Efficacy and safety of risperidone sustained-release tablets of Paley and perphenazine in the treatment of first-episode schizophrenia. Methods 69 patients with first-episode schizophrenia were randomly divided into Paley, risperidone sustained-release tablets group 34 cases and Perphenazine group 35 cases, using Paley risperidone sustained-release tablets and Perphenazine in the treatment, the positive and negative symptom scale （PANSS） and Treatment Emergent Symptom Scale （TESS） in the ther- apy and assess the clinical effect and adverse reactions. Treatment time was 8 weeks. Results The two groups after treatment PANSS score decreased significantly at the end of treatment （P 〈 0.01 ）. Paley risperidone sustained-release tablets group and perphenazine group of significant efficiency were 77% and 71.7% , the total effective rate were 94. 8% and 91.9% , there was no significant difference between the two groups （P 〉0. 05）. There was no significant difference between the two groups of TESS （ P 〉 0. 05 ）. Conclusion Certainly Paley risperidone sustained-release tablets in the treatment of first-episode schizophrenia effect, high safety, provides a new choice for the treatment of schizophrenia.

关 键 词：精神分裂症 帕利哌酮缓释片 奋乃静 疗效 

分 类 号：R749.3[医药卫生—神经病学与精神病学]